Metabolic Syndrome and COVID-19

被引：48

作者：

Yanai, Hidekatsu ^{[1
]}

机构：

[1] Kohnodai Hosp, Natl Ctr Global Hlth & Med, Dept Diabet Endocrinol & Metab, 1-7-1 Kohnodai, Ichikawa, Chiba 2728516, Japan

来源：

CARDIOLOGY RESEARCH | 2020年 / 11卷 / 06期

基金：

英国医学研究理事会;

关键词：

Adipocytokines; COVID-19; Cytokines; Metabolic syndrome; Endothelial dysfunction;

D O I：

10.14740/cr1181

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Recent studies showed that comorbidities such as diabetes, hypertension and obesity contribute to severe and worse outcomes of coronavirus disease 2019 (COVID-19), suggesting that metabolic syndrome and its components are associated with severity of COVID-19. Here, I systematically reviewed a possible association of metabolic syndrome with the susceptibility to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and severity of COVID-19 by literature search. A population-based study and UK Biobank studies showed that patients with metabolic syndrome is highly susceptible to SARS-CoV-2 infection. Recent meta-analyses showed that metabolic syndrome is significantly associated with the development of severe COVID-19. Angiotensin-converting enzyme (ACE) 2 is the cellular entry receptor of SARS-CoV-2. Enhanced ACE2 expression, pre-existing endothelial dysfunction and procoagulant state induced by adipocytokines dysregulation in metabolic syndrome may play a crucial role for the development of severe COVID-19.

引用

页码：360 / 365

页数：6

共 37 条

[11] A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers [J].

Grover, Abhinav ;

Oberoi, Mansi .

EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2021, 7 (02) :148-157

[12] Dyslipidemia is associated with severe coronavirus disease 2019 (COVID-19) infection [J].

Hariyanto, Timotius Ivan ;

Kurniawan, Andree .

DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2020, 14 (05) :1463-1465

[13] Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis [J].

Henry, Brandon Michael ;

de Oliveira, Maria Helena Santos ;

Benoit, Stefanie ;

Plebani, Mario ;

Lippi, Giuseppe .

CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2020, 58 (07) :1021-1028

[14] Increased ACE2 Expression in Bronchial Epithelium of COPD Patients who are Overweight [J].

Higham, Andrew ;

Singh, Dave .

OBESITY, 2020, 28 (09) :1586-1589

[15] Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19 [J].

Kai, Hisashi ;

Kai, Mamiko .

HYPERTENSION RESEARCH, 2020, 43 (07) :648-654

[16]

Leong Aaron, 2020, medRxiv, DOI 10.1101/2020.08.26.20182709

[17] Thrombosis and coagulopathy in COVID-19: An illustrated review [J].

Levi, Marcel ;

Hunt, Beverley J. .

RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2020, 4 (05) :744-751

[18] Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers and outcomes in patients with COVID-19: a systematic review and meta-analysis [J].

Lo, Kevin Bryan ;

Bhargav, Ruchika ;

Salacup, Grace ;

Pelayo, Jerald ;

Albano, Jeri ;

McCullough, Peter A. ;

Rangaswami, Janani .

EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2020, 18 (12) :919-930

[19] Interleukin-6 and severe COVID-19: a systematic review and meta-analysis [J].

Mojtabavi, Helia ;

Saghazadeh, Amene ;

Rezaei, Nima .

EUROPEAN CYTOKINE NETWORK, 2020, 31 (02) :44-49

[20] Clinical laboratory parameters associated with severe or critical novel coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis [J].

Moutchia, Jude ;

Pokharel, Pratik ;

Kerri, Aldiona ;

McGaw, Kaodi ;

Uchai, Shreeshti ;

Nji, Miriam ;

Goodman, Michael .

PLOS ONE, 2020, 15 (10)

← 1 2 3 4 →